Ajanta Pharma Announces the Launch of Aripiprazole Tablets
Bridgewater : Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces the launch of Aripiprazole Tablets (2.5mg, 5mg, 10mg, 15mg, 20mg, 30mg), a bioequivalent generic version of Abilify®, into the US market.
Aripiprazole Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated New Drug Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the United States Food & Drug Administration.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd